

Sanja Dacic

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9190804/sanja-dacic-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

9,014
citations

41
h-index

94
g-index

126
ext. papers

11,360
ext. citations

4.7
avg. IF

5.88
L-index

#	Paper	IF	Citations
114	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 823-59	8.9	632
113	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1302-1311	8.9	381
112	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 129-159	5	371
111	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013 , 137, 823-829	5	365
110	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 129-159	5.1	340
109	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 89-108	5	315
108	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018 , 8, 1548-1565	24.4	258
107	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 323-358	8.9	241
106	Overexpression of Dicer in precursor lesions of lung adenocarcinoma. <i>Cancer Research</i> , 2007 , 67, 2345-50	10.1	212
105	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 129-159	5.1	165
104	Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. <i>Modern Pathology</i> , 2008 , 21, 742-7	9.8	165
103	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. <i>Modern Pathology</i> , 2012 , 25, 1574-83	9.8	155
102	Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8001-8001	2.2	150
101	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. <i>Modern Pathology</i> , 2010 , 23, 1577-82	9.8	119
100	Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5294-300	2.2	116
99	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 499-519	8.9	99
98	Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. <i>Modern Pathology</i> , 2010 , 23, 159-68	9.8	98

97	Significance of EGFR Protein Expression and Gene Amplification in Non-small Cell Lung Carcinoma. <i>American Journal of Clinical Pathology</i> , 2006 , 125, 860-865	1.9	98
96	The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. <i>American Journal of Clinical Pathology</i> , 2011 , 135, 619-27	1.9	95
95	Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. <i>American Journal of Surgical Pathology</i> , 2002 , 26, 510-6	6.7	94
94	Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008 , 453, 627-35	5.1	93
93	The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. <i>Modern Pathology</i> , 2016 , 29, 14-24	9.8	86
92	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1409-1424	8.9	80
91	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 709-740	8.9	77
90	CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. <i>Modern Pathology</i> , 2010 , 23, 531-8	9.8	72
89	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. <i>Human Pathology</i> , 2010 , 41, 94-102	3.7	71
88	Revolution in lung cancer: new challenges for the surgical pathologist. <i>Archives of Pathology and Laboratory Medicine</i> , 2011 , 135, 110-6	5	62
87	Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. <i>American Journal of Clinical Pathology</i> , 2011 , 135, 783-9	1.9	61
86	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 29-49	8.9	58
85	Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas. <i>American Journal of Clinical Pathology</i> , 2015 , 143, 193-200; quiz 306	1.9	54
84	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1599-1610	8.9	52
83	Patterns of allelic loss of synchronous adenocarcinomas of the lung. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 897-902	6.7	51
82	Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1549-1553	5	50
81	MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020 , 33, 245-254	9.8	50
80	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. <i>Oncotarget</i> , 2016 , 7, 82943-82952	3.3	49

79	Postoperative fluorescence bronchoscopic surveillance in non-small cell lung cancer patients. <i>Annals of Thoracic Surgery</i> , 2001 , 71, 967-70	2.7	44
78	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. <i>Modern Pathology</i> , 2016 , 29, 735-42	9.8	43
77	EGFR assays in lung cancer. <i>Advances in Anatomic Pathology</i> , 2008 , 15, 241-7	5.1	42
76	Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections. <i>Modern Pathology</i> , 2015 , 28, 1058-63	9.8	41
75	Malignant mesothelioma in situ: morphologic features and clinical outcome. <i>Modern Pathology</i> , 2020 , 33, 297-302	9.8	41
74	Fluorescence bronchoscopic surveillance after curative surgical resection for non-small-cell lung cancer. <i>Annals of Surgical Oncology</i> , 2000 , 7, 176-80	3.1	40
73	The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. <i>Human Pathology</i> , 2017 , 67, 160-168	3.7	37
72	Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification. <i>Cancer Cytopathology</i> , 2013 , 121, 629-37	3.9	36
71	KRAS mutant allele-specific imbalance in lung adenocarcinoma. <i>Modern Pathology</i> , 2011 , 24, 1571-7	9.8	36
70	Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. <i>American Journal of Clinical Pathology</i> , 2006 , 125, 860-5	1.9	35
69	Malignant mesothelioma in situ. <i>Histopathology</i> , 2018 , 72, 1033-1038	7.3	34
68	Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. <i>Breast Journal</i> , 2002 , 8, 376-81	1.2	34
67	Loss of heterozygosity patterns of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicate a similar molecular pathogenesis. <i>Archives of Pathology and Laboratory Medicine</i> , 2004 , 128, 880-4	5	34
66	Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. <i>Modern Pathology</i> , 2017 , 30, 329-339	9.8	31
65	Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology,	5	31
64	Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. <i>Journal of Clinical Pathology</i> , 2013 , 66, 870-4	3.9	31
63	Pulmonary preneoplasia. <i>Archives of Pathology and Laboratory Medicine</i> , 2008 , 132, 1073-8	5	31
62	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29

61	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1037-1053	8.9	27
60	Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation. <i>Human Pathology</i> , 2002 , 33, 927-32	3.7	27
59	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	26
58	Targeted Therapies in Lung Cancer. <i>Surgical Pathology Clinics</i> , 2010 , 3, 71-82	3.9	25
57	Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2. <i>American Journal of Clinical Pathology</i> , 2012 , 138, 712-8	1.9	25
56	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. <i>Human Pathology</i> , 2010 , 41, 1053-60	3.7	24
55	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. <i>Neoplasia</i> , 2015 , 17, 817-25	6.4	23
54	KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. <i>Modern Pathology</i> , 2014 , 27, 262-70	9.8	22
53	Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. <i>Histopathology</i> , 2016 , 68, 729-37	7.3	22
52	Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples. <i>Advances in Anatomic Pathology</i> , 2018 , 25, 24-30	5.1	22
51	Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 24063-24076	3.3	21
50	Molecular diagnostics of lung carcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2011 , 135, 622-9	5.9	21
49	RET rearrangements in lung adenocarcinoma and radiation. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 118-20	8.9	20
48	Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. <i>Cancer Cytopathology</i> , 2020 , 128, 126-132	3.9	19
47	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2015 , 4, 34	7.8	18
46	Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. <i>American Journal of Clinical Pathology</i> , 2014 , 141, 420-8	1.9	18
45	Cytopathology of pulmonary adenocarcinoma with a single histological pattern using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification. <i>Cancer Cytopathology</i> , 2015 , 123, 306-17	3.9	17
44	Present and future molecular testing of lung carcinoma. <i>Advances in Anatomic Pathology</i> , 2014 , 21, 94-9	5.1	17

43	Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 353-357	5	17
42	KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. <i>Histopathology</i> , 2018 , 73, 207-214	7.3	16
41	Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 77-86	3.8	15
40	Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. <i>Modern Pathology</i> , 2020 , 33, 255-262	9.8	15
39	Minimally invasive adenocarcinomas of the lung. <i>Advances in Anatomic Pathology</i> , 2009 , 16, 166-71	5.1	13
38	Histologic classification of idiopathic chronic interstitial pneumonias. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003 , 29, S5-9	5.7	13
37	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 550-554	4.7	11
36	Pleural mesothelioma classification update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 478, 59-72	5.1	11
35	Histopathologic and molecular approach to staging of multiple lung nodules. <i>Translational Lung Cancer Research</i> , 2017 , 6, 540-549	4.4	10
34	Dilemmas in lung cancer staging. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 1194-7	5	10
33	Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity. <i>Experimental and Molecular Pathology</i> , 2005 , 78, 135-9	4.4	10
32	Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. <i>Histopathology</i> , 2019 , 74, 269-275	7.3	9
31	Reproducibility for histologic parameters in peritoneal mesothelioma. <i>Human Pathology</i> , 2017 , 67, 54-59	3.7	9
30	Microsatellite instability is uncommon in lymphoepithelioma-like carcinoma of the lung. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 282-6	1.9	9
29	Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. <i>Cancer Cytopathology</i> , 2020 , 128, 939-947	3.9	9
28	A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis. <i>Histopathology</i> , 2017 , 71, 269-277	7.3	8
27	The 2021 World Health Organization Classification of Tumors of the Pleura: Advances since the 2015 Classification.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	8
26	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021 , 53, 446-453	1.6	8

25	Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA. <i>Future Oncology</i> , 2021 , 17, 4045-4055	3.6	8
24	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020 , 144, 1477-1489	5	7
23	FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 55-61	1.9	7
22	Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ. <i>Lung Cancer</i> , 2020 , 149, 1-4	5.9	7
21	Sex-determining region Y-box 2 amplification in preneoplastic squamous lesions of the lung. <i>Human Pathology</i> , 2013 , 44, 706-11	3.7	5
20	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 989-999	1.9	5
19	Pleural mesothelioma classification-update and challenges. <i>Modern Pathology</i> , 2021 ,	9.8	5
18	Malignant Mesothelioma In Situ: Clinical and Pathologic Implications. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 899-901	8.9	4
17	Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas. <i>Lung Cancer</i> , 2020 , 143, 12-18	5.9	4
16	HepPar-1 expression in primary lung adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2013 , 140, 225-30	1.9	3
15	Artificial intelligence (AI)-powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 106-106	2.2	3
14	Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e135-e136	8.9	2
13	Immunohistology of Lung and Pleural Neoplasms 2011 , 369-463		2
12	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 686-696	8.9	2
11	Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. <i>Modern Pathology</i> , 2021 , 34, 2028-2035	9.8	2
10	Molecular characterization of pleomorphic mesothelioma: a multi-institutional study. <i>Modern Pathology</i> , 2021 ,	9.8	2
9	Lung Carcinoma Staging Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 923-926	5	1
8	Evaluation of Small Biopsy Material in Patients with Multiple and Secondary Tumors 2015 , 155-196		1

7	Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e9-e10	8.9	1
6	State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma. <i>Cytopathology</i> , 2021 ,	1.3	1
5	Solid papillary mesothelial tumor. <i>Modern Pathology</i> , 2021 ,	9.8	1
4	Molecular Prognostic Markers of Lung Cancer. <i>Molecular Pathology Library</i> , 2012 , 109-111		0
3	Molecular Aspects of Malignant Mesothelioma and Other Tumors of the Pleura and Peritoneum 106-114		
2	The HGF-MET signaling pathway is enriched in LUAC brain metastases.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20597-e20597	2.2	
1	Association of chromosome 17 copy number instability with favorable prognosis in nonsurgically treated gastroesophageal adenocarcinoma and impaired response to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 61-61	2.2	